Detection in Fecal DNA of Colon Cancer–Specific Methylation of the Nonexpressed Vimentin Gene

Chen, Wei Dong; Han, Ze‐Guang; Skoletsky, Joel; Olson, Jeff; Sah, Jerome F.; Myeroff, Lois; Platzer, Petra; Lu, Shi‐Long; Dawson, Dawn M.; Willis, Joseph E.; Pretlow, Theresa P.; Lutterbaugh, James; Kasturi, Lakshmi; Willson, James K.V.; Rao, Jun; Shuber, Anthony P.; Markowitz, Sanford D.

doi:10.1093/jnci/dji204

Cited by 333 publications

(248 citation statements)

References 27 publications

Supporting

Mentioning

237

Contrasting

Order By: Relevance

“…16 In addition, the mutation marker panel could be reduced in size by including epigenetic markers. 17 Indeed, the lessons learned from the current study could be applied to optimize quantitative assays for methylation-based BEAMing or for any other tests for tumor-specific DNA variations that are developed in the future.…”

Section: Discussionmentioning

confidence: 99%

Analysis of Mutations in DNA Isolated From Plasma and Stool of Colorectal Cancer Patients

et al. 2008

View full text Add to dashboard Cite

Background & Aims-Somatic mutations provide uniquely specific markers for the early detection of neoplasia that can be detected in DNA purified from plasma or stool of patients with colorectal cancer. The primary purpose of the present investigation was to determine the parameters that were critical for detecting mutations using a quantitative assay. A secondary purpose was to compare the results of plasma and stool DNA testing using the same technology.

show abstract

Section: Discussionmentioning

confidence: 99%

Analysis of Mutations in DNA Isolated From Plasma and Stool of Colorectal Cancer Patients

et al. 2008

View full text Add to dashboard Cite

show abstract

“…The gap between the general possibility of early detection and the persistent high mortality rates is due to limited sensitivity or specificity of existing tests, such as screening for fecal occult blood (FOBT) 2 , or due to an unfortunate lack of compliance for others, for instance colonoscopy 3, 4 . Therefore, several additional approaches for early detection are being pursued, such as the detection of genetically or epigenetically altered genes in stool samples 23,24 , and the presence of cancer cells or abnormal proteins in the peripheral blood 25 . While promising, none of these approaches has resulted in the implementation of complementary screening tests to digital rectal examination, colonoscopy, and FOBT.…”

Section: Discussionmentioning

confidence: 99%

Increased Serum Levels of Complement C3a Anaphylatoxin Indicate the Presence of Colorectal Tumors

et al. 2006

View full text Add to dashboard Cite

show abstract

“…Fecal SFRP2 methylation also drops dramatically after surgery [postoperative: 8.7% (6/69) vs preoperative: 87% (60/69)] [52] , suggesting its possible utility as a biomarker for recurrence. The vimentin gene, which encodes an intermediate filament protein involved in cell attachment, migration, and signaling, was identified in the stool of 83% of CRC patients with a specificity of 90% [62] . Since then, many studies have been devoted to vimentin methylation.…”

Section: Biomarkers Of Dna Methylation In Bloodmentioning

confidence: 99%

Advances in epigenetic biomarker research in colorectal cancer

Kuang

2014

WJG

View full text Add to dashboard Cite

Colorectal cancer (CRC) causes approximately 600000 deaths annually and is the third leading cause of cancer mortality worldwide. Despite significant advancements in treatment options, CRC patient survival is still poor owing to a lack of effective tools for early diagnosis and a limited capacity for optimal therapeutic decision making. Since there exists a need to find new biomarkers to improve diagnosis of CRC, the research on epigenetic biomarkers for molecular diagnostics encourages the translation of this field from the bench to clinical practice. Epigenetic alterations are thought to hold great promise as tumor biomarkers. In this review, we will primarily focus on recent advances in the study of epigenetic biomarkers for colorectal cancer and discuss epigenetic biomarkers, including DNA methylation, microRNA expression and histone modification, in cancer tissue, stool, plasma, serum, cell lines and xenografts. These studies have improved the chances that epigenetic biomarkers will find a place in the clinical practices of screening, early diagnosis, prognosis, therapy choice and recurrence surveillance for CRC patients. However, these studies have typically been small in size, and evaluation at a larger scale of well-controlled randomized clinical trials is the next step that is necessary to increase the quality of epigenetic biomarkers and ensure their widespread clinical use.

show abstract

Detection in Fecal DNA of Colon Cancer–Specific Methylation of the Nonexpressed Vimentin Gene

Abstract: Aberrant methylation of exon-1 sequences within the nontranscribed vimentin gene is a novel molecular biomarker of colon cancer and can be successfully detected in fecal DNA to identify nearly half of individuals with colon cancer.

Cited by 333 publications

References 27 publications

Analysis of Mutations in DNA Isolated From Plasma and Stool of Colorectal Cancer Patients

Analysis of Mutations in DNA Isolated From Plasma and Stool of Colorectal Cancer Patients

Increased Serum Levels of Complement C3a Anaphylatoxin Indicate the Presence of Colorectal Tumors

Advances in epigenetic biomarker research in colorectal cancer

Contact Info

Product

Resources

About